Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
This is a multi-center, randomized, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of Fluticasone Furoate Inhalation Powder 100mcg once daily and Fluticasone Propionate Inhalation Powder 250mcg twice daily with Placebo. Subjects will participate in the study for up to a maximum of 29 weeks (including screening, treatment and follow-up contact). The primary endpoint consists of change from baseline in clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at the end of the 24 week treatment period. The nominated powered secondary endpoint is the change from baseline in the percentage of rescue-free 24 hour periods during the 24-week treatment period. Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry and urine cortisol excretion. For subjects who have consented for pharmacogenetics, a blood sample will also be taken for pharmacogenetic analysis.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
Outpatient at least 12 years of age
Both genders; females of child bearing potential must be willing to use approved birth control method
Pre-bronchodilator FEV1 of 40-90% predicted
Reversibility FEV1 of at least 12% and 200mLs
Current asthma therapy that includes an inhaled corticosteroid for at least 4 weeks prior to first visit
You may not be if
History of life threatening asthma
Respiratory infection or candidiasis
Asthma exacerbation within 6 months prior to first visit
Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
Allergies to study drugs, study drug excipients, medications related to study drugs
Taking another investigational medication or medication prohibited for use during this study